Swiss National Bank Reduces Position in Progyny, Inc. (NASDAQ:PGNY)

Swiss National Bank lessened its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 150,900 shares of the company's stock after selling 16,400 shares during the quarter. Swiss National Bank owned approximately 0.18% of Progyny worth $2,603,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of PGNY. Invenomic Capital Management LP acquired a new position in shares of Progyny during the third quarter worth $29,509,000. River Road Asset Management LLC acquired a new position in Progyny in the fourth quarter valued at approximately $25,529,000. Pacer Advisors Inc. boosted its holdings in shares of Progyny by 47.5% during the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after buying an additional 1,183,558 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after buying an additional 695,740 shares during the period. Finally, Barclays PLC increased its stake in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after acquiring an additional 594,140 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PGNY. Bank of America increased their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research note on Monday. Canaccord Genuity Group upped their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Progyny currently has a consensus rating of "Hold" and an average target price of $23.64.

Remove Ads

Progyny Price Performance

Shares of Progyny stock traded up $0.44 during trading hours on Monday, hitting $22.34. 1,951,995 shares of the company's stock traded hands, compared to its average volume of 1,697,203. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.52, a PEG ratio of 2.39 and a beta of 1.41. The company has a fifty day simple moving average of $22.09 and a 200-day simple moving average of $18.50. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $37.92.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.